MAPK3 and head and neck squamous cell carcinoma: Phosphorylated Erk1/2 can be found in more than 90% of patients with HNSCC [27,30], and the activation of Erk1/2 is associated with the more aggressive behavior of the tumors, the increased development of recurrences, and advanced nodal stages [27,30,31].